UroGen Pharma Ltd (URGN): Konsensus nilai wajar

The historical price action of UroGen Pharma Ltd. (URGN) reflects market expectations, with the current indicator standing at 59.85. UroGen Pharma Ltd. (URGN) develops advanced therapies for urinary tract tumors, utilizing a unique RTGel to prolong drug action without the need for surgery. The brand's high authority in urological oncology is bolstered by the safety of its hydrogel systems, while the business remains virtually immune to external political risks due to the humanitarian status of its developments.

Bagan rega target UroGen Pharma Ltd (URGN): kanggo periode 04.07.2022 - 22.10.2026

Rincian analitis perusahaan UroGen (URGN)

Indikator analitis utama UroGen Pharma Corp (URGN):

Rega saham urogen.com|URGN - Bagan rega target|Nilai pasar UroGen

Analisis fundamental perusahaan:urogen.com (URGN)

Produk asli UroGen

Investors often waver between the current market price and an asset's growth potential. This consensus forecast indicator aggregates independent expert estimates to determine the business's fundamental value, stripped of market emotional pressure. This chart reflects the company's resilience to external shocks via the weighted average target price. For UroGen Pharma Ltd. (URGN), such a valuation is based on the commercialization of its unique gel drug delivery technology, allowing market expectations to be compared with the actual market penetration within urological oncology.

Perusahaan pesaing

Prakiraan konsensus analis beigene.com (ONC)|Bagan rega target Halozyme HALO|Konsensus nilai wajar RVMD|Ascentage - Prakiraan konsensus analis|Rentang target analis CG Oncology Therapeutics (CGON)|Bicara Therapeutics Inc. (BCAX) - Bagan rega target|Prakiraan gabungan firma investasi PSNL|ERAS (Erasca) - Prakiraan konsensus analis|Target konsensus Delcath Systems Inc (DCTH)|Prakiraan konsensus analis YMAB|Prakiraan konsensus analis Aura Corp (AURA)|Bagan rega target Candel Therapeutics, Inc. CADL|ARAY: Prakiraan gabungan firma investasi|SELLAS Life Sciences Group Inc. - Prakiraan konsensus analis|Actuate Therapeutics Inc. (ACTU) - Target konsensus|CTOR: Prakiraan konsensus analis|Rata-rata rega prakiraan TuHURA Biosciences (HURA)|Bagan rega target Protara Therapeutics|FATE: Konsensus nilai wajar|Target konsensus WHWK (Aadi Bioscience Inc)|TCRX (tscan.com) - Konsensus nilai wajar|Prakiraan konsensus analis CSBR (Champions Oncology, Inc.)|XBIT - Target konsensus|CVM: Target konsensus|OSTX - Prakiraan konsensus analis|Radiopharm Theranostics Limited (RADX) - Bagan rega target|Artiva Biotherapeutics - Konsensus nilai wajar|ANL (Adlai Nortye Ltd) - Prakiraan konsensus analis|Rata-rata rega prakiraan Veru Corporation VERU|Target konsensus TPST (Tempest Therapeutics)|Prakiraan konsensus analis xiliotx.com (XLO)|Bagan rega target Renovaro RENB|Konsensus nilai wajar MURA|KAPA - Bagan rega target|Rata-rata rega prakiraan OnKure Therapeutics Inc|GDTC: Prakiraan konsensus analis|Rentang target analis Curis CRIS|APLM (Apollomics Inc.) - Prakiraan konsensus analis|Rata-rata rega prakiraan Tharimmune Inc THAR|Bagan rega target Advanced Biomed Inc (ADVB)|Genprex Inc - Prakiraan gabungan firma investasi|Calidi Biotherapeutics, Inc. - Target konsensus|Konsensus nilai wajar SBFM|XBIO - Bagan rega target|Bagan tingkat prakiraan SLRX|PPBT: Prakiraan konsensus analis|American Oncology Network, Inc. - Konsensus nilai wajar|BGNE (BeiGene, Ltd.) - Prakiraan konsensus analis|Prakiraan konsensus analis checkpointtx.com|Bagan rega target Elevation Oncology, Inc. (ELEV)|ICAD (icadmed.com) - Konsensus nilai wajar|Bagan rega target Ikena Oncology IKNA|NTBL - Target konsensus|Viracta - Prakiraan konsensus analis|MOR - Prakiraan konsensus analis|NAYA (NAYA Biosciences Inc.) - Target konsensus|Ascentage Pharma Group International - Konsensus nilai wajar